Enterprise P&T Meeting Committee Meeting Minutes February 5, 2024

Voting Members Present

Christopher Antypas, PharmD	David Batluck, DO	Floyd (John) Brinley, MD	Kirt Caton, MD	Donald Cooper, PharmD
Tracey Davis, PharmD	Fury Fecondo, PharmD	Robert Hockmuth, MD	Emily Kryger, PharmD	Lenaye Lawyer, MD
Kelly Martin, PharmD	Michelle Murphy, PharmD	Eric Peters, PharmD	Andrew Peterson, PharmD	David Petkash, MD
Christy Skibicki, MD	Loretta Sonnier, MD	Rani Whitfield, MD		

Excused Voting Members

Michael Baer, MD	Donald Beam, MD	Rogers Elebra, PharmD	Kendra Michael, MD	Yavar Moghimi, MD
Kirby Smith, MD	Wayne Weart, PharmD			


Invited Guests Present


Christian Andreaggi, PharmD	Bethany Baird, CPhT	Linda Carreras, CPhT	Sheena Cherian, PharmD	Kathleen Clement
Mike Colvin, PharmD	Natalie Dick, CPhT	Rajneel Farley, PharmD	Amanda Hunter, PharmD	Toks Kassim, PharmD
Lisa Kazakis	Jeffrey Kreitman, PharmD	Lauren Megargell, PharmD	Melissa Megrdichian, PharmD	Christopher Meny, PharmD
Patty Oaster	Sarah Pawlak, PharmD	Victoria Pinkovsky	Jeanine Plante, PharmD	Ally Seitz, PharmD
Ruth Smith, PharmD	Luke Stadler, PharmD	Mali Thomas, CPhT	Erich Weiss, PharmD	Arlene Wiseman, PharmD


Issue	Discussion	Conclusion/Results	Action/ Person Responsible
1. Call to Order	The meeting was called to order at 6:02 PM EST.	Informational Only	Lenaye Lawyer
	Welcomed all external and internal participants.		
2. Conflict of Interest Disclosure	No conflicts announced	Informational Only	Jeffrey Kreitman
4. Review and approval of Oct. P&T, Dec. and Jan. Proxy Minutes		Committee approved as recommended:	Jeffrey Kreitman
		Motion: Donald Cooper Second: Robert Hockmuth	
5. Old Business			


6. New Business Pompe Disease Agents	PerformRx makes the following recommendations:	Committee approved as recommended: Motion: David Batluck Second: Robert Hockmuth	PerformRx will update the criteria and formulary/PDL with any changes

	KF/AHC • Approve the newly developed Pompe Disease Agents prior authorization criteria.		
Qlosi – Presbyopia Agents	PerformRx makes the following recommendations:	Committee approved as recommended: Motion: David Batluck Second: Robert Hockmuth	PerformRx will update the criteria and formulary/PDL with any changes














Antitussives/Expectorants	PerformRx makes the following recommendations:	Committee approved as recommended: Motion: Kirt Caton Second: Donald Cooper	PerformRx will update the criteria and formulary/PDL with any changes













Lyfgenia with PA Criteria	PerformRx makes the following recommendations:	Committee approved as recommended: Motion: Kirt Caton Second: Donald Cooper	PerformRx will update the criteria and formulary/PDL with any changes





Sohonos with PA Criteria	PerformRx makes the following recommendations:	Committee approved as recommended: Motion: Kirt Caton Second: Donald Cooper	PerformRx will update the criteria and formulary/PDL with any changes

Rivfloza with PA Criteria	KF/AHC/ : • Add Sohonos to T4 of the formulary with a prior authorization requirement. • Approve the newly developed Sohonos prior authorization criteria. • PerformRx makes the following recommendations:	Committee approved as recommended: Motion: Kirt Caton Second: Donald Cooper	PerformRx will update the criteria and formulary/PDL with any changes
Rivfloza with PA Criteria		recommended: Motion: Kirt Caton	update the criteria and formulary/PDL





Zurzuvae with PA Criteria	PerformRx makes the following recommendations:	Committee approved as recommended:Motion: Kirt Caton Second: Donald CooperComments and discussion:David Petkash comment: Psychiatrist should be approving the request.Loretta Sonnier comment: Discussion on how to manage redosing after six months. No data on redosing and the drug is limited to a one-time treatment.Jeff Kreitman comment: From operational standpoint the request will not be approved based on the criteria. Appeal request will be evaluated.Lauren Megargell comment:	PerformRx will update the criteria and formulary/PDL with any changes





 Add Zurzuvae to Tier 3 of the formulary with a prior authorization requirement. Update the Zulresso prior authorization criteria to include Zurzuvae. Update the title from Zulresso to Agents for the Treatment of Postpartum Depression to account for multiple agents addressed in the policy. Add Zurzuvae to the drug list. Update age restrictions to align with package inserts for both agents. Update coverage duration to allow for a 14-day course of Zurzuvae. Update diagnosis requirement to severe postpartum depression validated by a screening tool and where the patient cannot wait 4-6 weeks for the standard of care antidepressants to take effect. Patient will be no more than 6 months postpartum. Add attesting for Zurzuvae requests that the patient was advised not to
drive after each dose to align with black box warning.







	Remain non-formulary/non-preferred for KF/AHC/ Adzynma Immphentiv Jylamvo Meropenem Pokonza Rezipres		
9. Prior Authorization Criteria Review			
A. Prior Authorization Annual Criteria			
KF.AHC. Compound Products	 PerformRx makes the following recommendations: KF/AHC/: Decrease the dollar limit to \$250 for compounded products that need a prior authorization review. 	Committee approved as recommended: Motion: David Batluck Second: Andrew Peterson	PerformRx will update the criteria and formulary/PDL with any changes


Gene Therapy for Hemophilia recommendations: recommended: upd	PerformRx will
	update the criteria nd formulary/PDL with any changes


	PerformRx makes the following	Committee approved as	PerformRx will
Glycopyrrolate	KF/AHC/:: Remove Dartisla ODT from the drug list and criteria as it was discontinued.	Motion: David Batluck Second: Andrew Peterson	update the criteria and formulary/PDL with any changes


Relyvrio	PerformRx makes the following recommendations:	Committee approved as recommended: Motion: David Batluck Second: Andrew Peterson	PerformRx will update the criteria and formulary/PDL with any changes





















	Image: Second state of the second s		
Blincyto	PerformRx makes the following recommendations:	Committee approved as recommended: Motion: David Batluck Second: Andrew Peterson	No Changes










	 KF/AHC/ Approve the Cystic Fibrosis transmembrane conductance regulator (CFTR) Modulators prior authorization criteria with no clinical changes. 		
Dojolvi	PerformRx makes the following recommendations:	Committee approved as recommended: Motion: David Batluck Second: Andrew Peterson	No Changes










recommendations:		No Changes
	recommended.	No Changes
	Motion: David Batluck	
	Second: Andrew Peterson	
		PerformRx makes the following recommendations: Committee approved as recommended: Motion: David Batluck Second: Andrew Peterson









Tavneos	PerformRx makes the following recommendations:	Committee approved as recommended:	No Changes
		Motion: David Batluck Second: Andrew Peterson	
	 KF/AHC/		







10. Recalls	10/23/2023 – 1/29/2024 Kilitch Healthcare India Limited Date 11/16/2023 Reason: Device & Drug Safety Potential Safety	Informational	PerformRx
	 Concerns Lubricating Tears Eye Drops 15ml Polyvinyl Alcohol 1.4% Lubricating Eye Drops 15 ml High Performance Lubricant Eye Drops 15 ml (Single Pack) 		
	 High Performance Lubricant Eye Drops 15 ml (Twin Pack) 		

Multi-Action Relief Drops 15ml	
Lubricating Gel Drops 10ml	
• Lubricant Eye Drops 10ml (Twin Pack)	
 Lubricant Gel Drops 15 Ml 	
• Lubricant Eye Drops 15ml (Twin Pack)	
• Eye Irritation Relief 15 ml	
• Dry Eye Relief 10 ml	
• Dry Eye Relief 15 ml	
• Lubricant Eye Drops 15 ML (Single	
Pack)	
• Lubricant Eye Drops 15 ML (Twin	
Pack)	
Lubricant Eye Drops 10ml	
• Lubricant Eye Drop 10ml (Triple Pack)	
• Lubricant Eye Drops 15ML (Single	
Pack)	
• Lubricant Eye Drops 15 ML (Twin	
Pack)	
• Lubricant Gel Drops 15 ml (Single	
Pack)	
• Lubricant Gel Drops 15 ml (Twin	
Pack)	
Multi Action Relief Drops 15ml	
Mild Moderate Lubricating Eye Drops	
15ml	
Lubricant Gel Drops 10ml	
• Lubricant Eye Drops 10ml (Single	
Pack)	
• Lubricant Eye Drops 10ml (Twin Pack)	
• Dry Eye Relief 15ml (Twin Pack)	
• Equate Hydration Pf Lubricant Eye	
Drops 10ml	

The Harvard Drug Group LLC dba Major	
Pharmaceuticals and Rugby Laboratories	
Date: 11/29/2023	
Reason:	
Non-Sterility: FDA found insanitary	
conditions and positive bacterial test results	
from environmental sampling at the	
manufacturing facility.	
Polyvinyl Alcohol 1.4% Lubricating	
Eye Drops	
• Lubricating Tears Eye Drops	
(Dextran/Hypromellose)	
Cardinal Health Inc	
Date: 11/29/2023	
Reason:	
Non-Sterility: FDA found insanitary	
conditions and positive bacterial test results	
from environmental sampling at the	
manufacturing facility.	
LEADER brand Eye Irritation Relief	
(Polyvinyl alcohol 0.5%, Povidone	
0.6%, Tetrahydrozoline Hydrochloride	
0.05%)	
• LEADER brand Dry Eye Relief	
(Carboxymethylcellulose Sodium, 1%)	
• LEADER brand Lubricant Eye Drops	
(Carboxymethylcellulose Sodium,	
0.5%)	
• LEADER brand Lubricant Eye Drops	
(Carboxymethylcellulose Sodium,	
0.5%)	

	 LEADER brand Dry Eye Relief (Polyethylene Glycol 400, 0.4% Propylene Glycol, 0.3%) LEADER brand Lubricant Eye Drops (Propylene Glycol, 0.6%) 	
11. Adjournment	The meeting adjourned at 7:07 PM EST	Lenaye Lawyer
	The next meeting April 29th, 2024 6:00 PM- 8:00	

Jeffy Matto Phan

5/23/24

Date

Enterprise P&T Meeting Committee Meeting Minutes Email Proxy Vote March 26, 2024

Committee Member	Approved	Reject	Excused	Committee Member	Approved	Reject	Excused
Andrew Peterson, PharmD				Kirby Smith, MD			
Christopher Antypas, PharmD	\boxtimes	\boxtimes		Kirt Caton, MD	\boxtimes		
David Batluck, DO	\boxtimes			Lenaye Lawyer, MD			
David Petkash, MD				Michael Baer/Alishia Richie Both approved but only one vote can be recorded.	\boxtimes	⊠ mifepr istone	
Don Cooper, RPh	\boxtimes			Michelle Murphy, PharmD	\boxtimes		
Donald Beam, MD	\boxtimes			Rani Whitfield, MD	\boxtimes		
Emily Kryger, PharmD	\boxtimes	\boxtimes		Robert Hockmuth, MD	\boxtimes		
Eric Peters, PharmD				Rodney Wise, MD			
Floyd (John) Brinley, MD	\boxtimes			Rogers Elebra, PharmD	\boxtimes		
Fury Fecondo, PharmD	\boxtimes			Tracey Davis, PharmD	\boxtimes	\boxtimes	
Kelly Martin, PharmD	\boxtimes			Wayne Weart, PharmD	\boxtimes	\square	
Kendra Michael, MD				Yavar Moghimi	\boxtimes		

Item	Recommendation	Vote Results	Action/ Person Responsible
COVID-19 Tests QL	• Lowering the QL from 8 down to 4 per month	Total Sent – 25 Total Responses – 18 Approved – 18 Rejected – 0 Excused – 7 End: 4/2/2024	PerformRx will implement per the outcome of the committee vote. The vote has been approved with 14 approvals and no
Dose Rounding Limit Exception Criteria	Language updates for clarity	Total Sent – 25 Total Responses – 18 Approved – 18 Rejected – 0 Excused – 7 End: 4/2/2024	rejections received. PerformRx will implement per the outcome of the committee vote. The vote has been approved with 14 approvals and no rejections received.
KF/AHC Mifepristone	Adding to the formulary for Pennsylvania per state requirements	Total Sent – 25 Total Responses – 18 Approved – 17	PerformRx will implement per the outcome of the committee vote.

Item	Recommendation	Vote Results	Action/ Person Responsible
		Rejected – 1	
		Excused – 7	The vote has been
			approved with 14
		End: 4/2/2024	approvals and 1
			rejection received.

leff Kreitman C Phan _ Jeff Kreitman, Chair

4/2/2024

Date